Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 20;16(22):3885.
doi: 10.3390/cancers16223885.

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Simone E Dekker  1   2 , Lei Deng  1   2
Affiliations
Review

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer

Simone E Dekker et al. Cancers (Basel). .

Erratum in

Abstract

KRAS mutation is one of the most common oncogenic drivers in non-small cell lung cancer. Since its discovery about four decades ago, drug development targeting KRAS has been met with countless failures. Recently, KRAS G12C, a subvariant of KRAS, became the first druggable KRAS mutation. The efficacy of the first-generation KRAS inhibitor is modest, but with scientific advancement, KRAS G12C inhibitors with higher potency are on the horizon. Additionally, novel therapeutic approaches targeting other KRAS subvariants are also being explored in clinical trials with encouraging early data. We will review the clinical advances and challenges for patients with KRAS-mutated non-small cell lung cancer, with a focus on small molecule inhibitors.

Keywords: G12C; KRAS; lung cancer; non-small cell lung cancer; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

L.D. declares the following conflicts of interest: Honoraria from MJH Life Sciences, Precisca; Consulting fees from Bristol-Myers Squibb, Regeneron; Travel from Merck, MJH Life Sciences; Institutional research funding from Bridgebio Oncology Therapeutics.

Figures

Figure 1
Figure 1
KRAS pathway and targets for treatment.
See this image and copyright information in PMC

References

    1. Prior I.A., Hood F.E., Hartley J.L. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969–2974. doi: 10.1158/0008-5472.CAN-19-3682. - DOI - PMC - PubMed
    1. Moore A.R., Rosenberg S.C., McCormick F., Malek S. RAS-Targeted Therapies: Is the Undruggable Drugged? Nat. Rev. Drug Discov. 2020;19:533–552. doi: 10.1038/s41573-020-0068-6. - DOI - PMC - PubMed
    1. de Langen A.J., Johnson M.L., Mazieres J., Dingemans A.-M.C., Mountzios G., Pless M., Wolf J., Schuler M., Lena H., Skoulidis F., et al. Sotorasib versus Docetaxel for Previously Treated Non-Small-Cell Lung Cancer with KRASG12C Mutation: A Randomised, Open-Label, Phase 3 Trial. Lancet. 2023;401:733–746. doi: 10.1016/S0140-6736(23)00221-0. - DOI - PubMed
    1. Jänne P.A., Riely G.J., Gadgeel S.M., Heist R.S., Ou S.-H.I., Pacheco J.M., Johnson M.L., Sabari J.K., Leventakos K., Yau E., et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N. Engl. J. Med. 2022;387:120–131. doi: 10.1056/NEJMoa2204619. - DOI - PubMed
    1. Solomon B.J., Liu G., Felip E., Mok T.S.K., Soo R.A., Mazieres J., Shaw A.T., de Marinis F., Goto Y., Wu Y.-L., et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J. Clin. Oncol. 2024;42:JCO2400581. doi: 10.1200/JCO.24.00581. - DOI - PMC - PubMed

LinkOut - more resources